EUVIMEDEuropean Health Evidence
Uhr Sources10/10 Journal Tree
Easy Demo

European Health Evidence

The European alternative to PubMed

EUVIMED is the European alternative to PubMed: a central, multilingual research platform for medicine, nursing, life sciences and healthcare. It brings together international and European literature sources, study registries, open-access full texts, citations and retraction notices in one search. Unlike pure bibliographic databases, EUVIMED supports the entire research process – from discovery and appraisal with LIVIA and CLARA to traceable evidence synthesis. European in focus, transparent, interoperable and designed for science and healthcare.

EuropeanMultilingualInteroperableTraceable

EUVIMED BETA

EUVIMED is currently in beta

EUVIMED is under continuous development. Features, data coverage and presentation may change or be temporarily incomplete.

Results are beta

Search results, classifications, summaries and AI-assisted assessments may be incomplete, delayed or incorrect.

Check original sources

Do not use EUVIMED results without verification for diagnosis, treatment or other clinical decisions. Always consult the original source and applicable guidelines.

Errors and feedback help us improve EUVIMED: info@euvimed.com

Lokaler Crossref-Datenbestand · journal-article

Phenotypic adaptation of clinical Pseudomonas aeruginosa to increasing ceftazidime exposure

Maxmillando Rymbai, Vedant V. Borah

International Journal of Basic & Clinical Pharmacology · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background: Pseudomonas aeruginosa readily adapts to antibiotic stress, but the effect of increasing ceftazidime exposure on colony morphology across specimen sources is poorly defined. This study determined whether ceftazidime alters growth and colony morphology in a concentration-dependent manner and whether the response varies by specimen source. Methods: Forty-eight non-duplicate clinical P. aeruginosa isolates from pus, wound swabs, urine, and tracheal aspirates were characterised for ceftazidime susceptibility, extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) production, and biofilm formation. Colony morphology was assessed after 24 hours on M9 agar with Congo red and Coomassie brilliant blue (RB medium), alone and with ceftazidime at one-half, one, and two times the isolate-specific minimum inhibitory concentration (MIC). Results: Ceftazidime resistance was 70.8%, ESBL production 47.9%, MBL production 33.3%, and strong biofilm formation 45.8%. Growth fell from 97.9% on RB medium to 45.8% at twice the MIC (p

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Maxmillando Rymbai, Vedant V. Borah
Quelle
International Journal of Basic & Clinical Pharmacology
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2279-0780, 2319-2003
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Maxmillando Rymbai, Vedant V. Borah (2026). Phenotypic adaptation of clinical Pseudomonas aeruginosa to increasing ceftazidime exposure. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20263255
RIS BibTeX CSL-JSON